EXUROCNCT07951060
LP-184 for Advanced or Metastatic Urothelial Carcinoma Selected by PTGR1 Expression and DNA Repair Deficiency
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Dose-Limiting Toxicity
Timeframe: During the first treatment cycle (21 days).
Recommended Phase II Dose (RP2D) of LP-184
Timeframe: During Phase Ib dose evaluation, up to approximately 6 months
Objective Response Rate (ORR) According to RECIST Version 1.1
Timeframe: From treatment initiation until disease progression or end of treatment, up to 1 year.
Secondary (3)
Progression-Free Survival (PFS)
Overall Survival (OS)
Duration of Response (DoR)
Arms and interventions
LP-184 armExperimental
All participants will receive LP-184 intravenously on days 1 and 8 of each 21-day treatment cycle. In Phase Ib, a modified 3+3 dose de-escalation design will be used to determine the recommended Phase II dose (RP2D). In Phase II, participants will receive LP-184 at the established RP2D.
Drugs: Intravenous infusion of LP-184 on Day 1 and Day 8 of a 21-day cycle.
Sites
1 site in 1 country
- Rigshospitalet, Phase 1 Unit, Department of Oncology, Section 5073. Address: Blegdamsvej 9, 2100 Copenhagen, DenmarkCopenhagen, Denmark